Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data

🌐 Fierce Biotech —
Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data

AI Summary

Inhibrx's clinical trial results show promising data from the combination treatment of its OX40 agonist with Keytruda. This positive outcome may boost investor confidence and influence the biotech market's direction.

Adding Inhibrx's OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the biotech to advance the ...

Markets Health AI & Tech Inhibrx clinical trial Keytruda cancer treatment biotechnology

Read original source →